Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
APGA Annual ConferenceAPGA Annual Conference
Not Confirmed
Not Confirmed
20-23 July, 2025
Not Confirmed
Not Confirmed
24-25 July, 2025
BIO Asia-TaiwanBIO Asia-Taiwan
Not Confirmed
Not Confirmed
24-27 July, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
APGA Annual ConferenceAPGA Annual Conference
Industry Trade Show
Not Confirmed
20-23 July, 2025
Industry Trade Show
Not Confirmed
24-25 July, 2025
BIO Asia-TaiwanBIO Asia-Taiwan
Industry Trade Show
Not Confirmed
24-27 July, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/50-years-of-innovation-mikart-s-legacy-and-what-s-next-in-cdmo-excellence
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/cdmo-activity-tracker-veranova-carbogen-lead-adc-investments-axplora-polfa-tarchomin-famar-expand-european-footprint
14 Jul 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250714581614/en/CEL-SCI-Announces-Closing-of-%245.7-Million-Offering-Priced-At-The-Market-Under-NYSE-American-Rules
18 Jun 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250618276691/en/FDAs-Approval-of-Keytruda-for-PD-L1-Positive-Head-and-Neck-Cancer-Patients-Signals-a-Clear-Pathway-for-CEL-SCIs-Multikine-to-Address-a-Major-Unmet-Need-in-PD-L1-Negative-Cancer-Patients
23 May 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250523121657/en/CEL-SCI-Announces-Closing-of-Public-Offering
21 May 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250521507461/en/CEL-SCI-Announces-Pricing-of-Public-Offering
21 May 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250521415690/en/CEL-SCI-Announces-Proposed-Public-Offering
21 May 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250521926714/en/CEL-SCIs-Multikine-Investigational-Cancer-Medicine-Potentially-Available-for-Commercialization-by-Summer-2025-in-Saudi-Arabia
ABOUT THIS PAGE
CEL-SCI is a supplier offers 1 products (APIs, Excipients or Intermediates).
Find a price of LEUKOCYTE INTERLEUKIN, INJECTION bulk offered by CEL-SCI